The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | KEYNOTE-799: pembro + chemoradiotherapy in locally advanced NSCLC
The ongoing Phase II KEYNOTE-799 trial (NCT03631784) of pembrolizumab with concurrent chemoradiation therapy in locally advanced, stage III non-small cell lung cancer showed promising overall response rates (ORR) for squamous and non-squamous cohorts in previously reported interim findings. Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, shares updated results from the trial with an additional 6 months of follow-up. Cohort A, consisting of patients with both squamous and non-squamous NSCLC, and cohort B, non-squamous only, had a median follow-up of 15.5 months and 13.5 months, respectively. The ORR was around 70% in both cohorts, regardless of tumor histology or PD-L1 tumor proportion score. The treatment was well tolerated with no new safety signals, and the median duration of response of yet to be reached. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
Disclosures
Honoraria: Amgen, AstraZeneca, Boehringer-Ingelheim, BMS, Lilly, Mirati, Merck, Novartis, Pfizer, Regeneron, Roche.
